PACIRA BIOSCIENCES, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.72M, a 9.75% increase year-over-year.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $1.23M, a 31.91% increase year-over-year.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $1.57M, a 15.03% increase year-over-year.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $2.80M, a 21.89% increase from fiscal 2024.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $2.30M, a 18.25% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $2.81M, a 4.84% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $2.95M, a 5.09% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $1.72M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.80M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | $1.57M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $934.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $1.36M 10-Q · filed 2025-08-05 | |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.81M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | |
| 2023-06-30 | $1.67M 10-Q · filed 2024-07-30 | |
| 2022-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.95M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | |
| 2022-06-30 | $1.82M 10-Q · filed 2023-08-02 | |
| 2021-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.81M 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2021-06-30 | $1.57M 10-Q · filed 2022-08-03 | |
| 2020-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.55M 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | |
| 2020-06-30 | $1.42M 10-Q · filed 2021-08-03 | |
| 2019-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.40M 10-K · filed 2022-02-28 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | |
| 2019-06-30 | $1.27M 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $832.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.78M 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | |
| 2018-06-30 | $952.00K 10-Q · filed 2019-08-08 | |
| 2017-12-31 | $806.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $1.86M 10-K · filed 2020-02-21 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | |
| 2016-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.50M 10-K · filed 2019-02-28 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | |
| 2015-12-31 | $898.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $2.09M 10-K · filed 2018-02-28 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | |
| 2014-12-31 | $1.18M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |